Diversity, Equity and Inclusion:
Increasing Gender Equality
We aim for pay equity at all levels. In 2021, Teva conducted comprehensive equitable pay research among 100% of our employees, which compared each employee and an equivalent colleague with the same profile and location. The findings revealed that among those in the same level, function/profession and location, Teva pays women 1% more than men for base salaries.
Teva also calculated mean payments of women compared to men, without considering level, function/profession and location. In this context, due to the influence of worldwide workforce demographics, the mean base salaries for men were 3% more than the base salaries for women. This gap is significantly ahead of the gap identified by Bloomberg Gender-Equality Index members, which shows men receive on average 21% more than women.
Climate Action and Resilience
In 2021, we reevaluated our climate targets and published new, more ambitious targets that we have committed to have validated by the Science Based Targets initiative (SBTi). These include reducing our scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025 and by 46% by 2030. We also committed to reducing scope 3 GHG emissions by 25% by 2030. In 2021, we reported our full scope 3 emissions for the first time, reflecting our efforts to increase transparency and measure reductions in GHG emissions across our value chain.
Assessing the Lifecycle of Products
packaging operations by 3,000 tons, equivalent to 72,000 trees, once the project is complete at the end of 2022.
Reducing Paper Waste
Teva US began implementing electronic medication guides for products in 2021, replacing the previous paper leaflets. This will significantly reduce the amount of paper used in Teva’s packaging operations by 3,000 tons, equivalent to 72,000 trees, once the project is complete at the end of 2022.
Integrating ESG into business strategy
• Reduce absolute scope 1 and 2 greenhouse gas (GHG) emissions by 25% by 2025 (vs. 2019)
Effluents and Waste
Access & Affordability:
Expanding Access to Medicines Program
Advancing Access to Behavioral Health Services
In June 2022, Teva launched its fifth access program – a new initiative in the US partnering with Direct Relief and NAFC to expand medication access and provide grant funding to free and charitable clinics that care for medically underserved patients suffering from depression and/or anxiety. The pilot program –initially in Florida, New Jersey and California – aims to help advance health equity for medically underserved populations.
Being a Trusted Partner During Emergencies and Disasters
We also help to address emergency situations, such as drug shortages, which can leave patients without access to medicines. In 2021, one of Teva’s suppliers for the active pharmaceutical ingredient in medicine to treat Wilson’s disease had product quality issues that led to a temporary drug shortage. To help patients during this time, Teva’s CAC worked to get US Food and Drug Administration approval to temporarily package and distribute the European equivalent product to US patients.
Supporting Humanitarian Efforts for Ukrainian Refugees
Integrating ESG into business strategy
• Increase the cumulative number of new regulatory submissions (2022–2025) in low- and middle-income countries (LMICs) on the World Health Organization’s Essential Medicines List across six key therapeutic areas by 150% by 2025 (vs. 2017–2020)
• Increase access to medicines program product volume by 150% in 2025 (vs. 2020) through four access to medicines programs, including donations and social business, in LMICs on the WHO EML across six key TAs
Advancing Access to Medicines
Teva supports nearly 200 million patients every day with a portfolio of over 2700 generic products including many that are on the WHO Essential Medicines List. In 2020, generic products helped patients and healthcare systems save more than $40 billion.